CellTherapies
Melbourne, Australia· Est.
Australia’s leading CDMO delivering GMP‑grade cell and gene therapies from early‑stage to commercial supply.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australia’s leading CDMO delivering GMP‑grade cell and gene therapies from early‑stage to commercial supply.
OncologyRegenerative MedicineImmunology
Technology Platform
Integrated GMP manufacturing platform for autologous and allogeneic cell and gene therapies, featuring closed‑system automation, digital twins, and cryopreservation logistics.
Opportunities
Rising demand for regional GMP cell‑therapy manufacturing in APAC and the company’s digital‑twin technology enable rapid scale‑up and cost‑effective production for emerging CAR‑T and iPSC programs.
Risk Factors
Regulatory changes, capacity constraints, and competition from larger multinational CDMOs could limit market share growth.
Competitive Landscape
Competes with global CDMOs such as Lonza, WuXi Biologics, and CMC Therapeutics; differentiates through its integrated end‑to‑end service model, digital transfer tools, and proximity to a leading cancer centre.